IQVIA Holdings Inc. has announced impressive financial results for the third quarter of 2026, showcasing significant growth in revenue and earnings. The company reported a revenue of $4,428 million, up 8.0% from the previous year, reflecting strong demand in the commercial physical and biological research sector. This performance is particularly noteworthy as IQVIA also raised its full-year guidance, signaling confidence in sustained growth.
Founded as Quintiles IMS Holdings, Inc., IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence. It operates under the Standard Industrial Classification of Services-Commercial Physical & Biological Research (SIC 8731) and trades on the New York Stock Exchange under the ticker symbol IQV. The company has been a significant player in the life sciences and healthcare industries, focusing on providing innovative solutions to its clients.
The recent filing reveals that IQVIA's revenue for the third quarter increased by 8.6% at constant currency, with notable contributions from its two main segments: Commercial Solutions and Research & Development Solutions (R&DS). The press release states, "IQVIA delivered another record quarter, with revenue, Adjusted EBITDA, and Adjusted Diluted EPS all exceeding the high end of our expectations." This highlights the company's strong operational execution and market positioning.
In terms of financial metrics, IQVIA reported a GAAP net income of $350 million, with an Adjusted EBITDA of $1,032 million, marking an 8.7% increase year-over-year. The company also reported a GAAP diluted earnings per share of $2.10 and an adjusted diluted earnings per share of $3.34, up 11.3% from the previous year. These figures reflect the company's robust financial health and effective cost management strategies.
The filing also noted that IQVIA's Commercial Solutions revenue was $1,789 million, an increase of 6.9% year-over-year, while R&DS revenue grew by 8.7% to $2,639 million. The company’s net new bookings for the quarter reached $3.2 billion, up 15% year-over-year, indicating a strong demand for its services and a favorable market environment.
IQVIA's successful quarter can be attributed to various factors, including favorable industry trends such as increased funding for Evidence-Based Practice (EBP), a rise in Requests for Proposals (RFPs), and a growing number of clinical trial starts and FDA approvals. The company's strategic focus on enhancing its AI-powered solutions has also played a crucial role, with over 400 AI agents deployed to date, contributing to its competitive edge in the market.
Looking ahead, IQVIA has raised its full-year guidance for revenue, Adjusted EBITDA, and Adjusted Diluted Earnings per Share. This optimistic outlook reflects the company’s confidence in its growth trajectory and market demand. The filing does not specify what happens next, but the company has scheduled an Investor Day for December 1, 2026, where it is expected to provide further insights into its strategic plans and future growth initiatives.
In conclusion, IQVIA's strong Q3 results and raised guidance not only highlight its leadership in the commercial physical and biological research industry but also set a high bar for competitors. As the company continues to leverage its innovative solutions and capitalize on favorable market conditions, it remains well-positioned for future growth.